The final report, presented to New York Governor Kathy Hochul, outlines a path to translate investments in the state's biotech ecosystem into real-world outcomes. Executives from The Michael J. Fox Foundation and Pfizer co-chaired the second iteration of this advisory board — which comprised 17 independent industry leaders — to develop the recommendations. NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of rec

Boehringer Ingelheim to expand R&D and pharmaceutical manufacturing, ensuring the bulk of its medicines for U.S. patients will be produced in the U.S. RIDGEFIELD, Conn., Dec. 19, 2025 /PRNewswire/ -- Boehringer Ingelheim, a 140-year-old family-owned biopharmaceutical company committed to improving human and animal health and advancing innovation, today announced a broad agreement with the Trump Administration to lower the cost of medicines for American patients, in line with the conditions set o

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response FDA has granted Hansa Biopharma Fast Track and Orphan Drug Designation and Hansa has requested Priority Review LUND, Sweden, Dec. 19, 2025 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Comp

Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation. The action satisfies the components outlined in President Trump's July 31 letter, including the Administration's Most Favored Nation pricing requests. Addition

HOUSTON, TX, UNITED STATES, December 19, 2025 / EINPresswire.com / -- Researchers are exploring whether dentists may one day use stem cells to help grow new teeth. While this idea once sounded out of reach, new studies show steady progress in restoring parts of a tooth, rebuilding dental pulp and supporting bone growth around the roots, with early findings outlined in a review by Zhang and Yelick published in Trends in Molecular Medicine (2021) Stem cells are repair cells that can renew and chan

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university BELLEVUE, Wash., Dec. 19, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings"), a global healthcare holding company, today announced that the shareholders of Woori IO Co., Ltd. ("Woori IO"), a leading Korean medical device innovator in noninvasive glucose monitoring technology, approved a share exchange at an Extr

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the “Special Meeting”). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to Januar

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Bags and Freezing Bags Market: Industry Trends and Global Forecasts - Distribution by Type of Analyte Stored and Key Geographical Regions" has been added to ResearchAndMarkets.com's offering. The global cryopreservation bags and freezing bags market is forecasted to expand from USD 216 million in 2023 to USD 316 million by 2035, reflecting a CAGR of 3.9% over the forecast period. This growth is driven by advancements in cryopreservation methods, whi

DeFloria Advancing Charlotte's Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug LOUISVILLE, Colo. and WASHINGTON, Dec. 19, 2025 /PRNewswire/ - DeFloria Inc., a botanical drug development Company recognizes the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, as a critical accelerator for cannabinoid medical innovation and regulatory reform. DeFloria is advancing a leading cannabinoid-based investigational new

Positioned to Accelerate Downgrading of Cannabinoid Medicine Scheduling. MONTEREY, Calif., Dec. 19, 2025 /PRNewswire/ -- BRC Therapeutics (BRC), a pharmaceutical company developing proprietary therapeutics for neurological and inflammatory diseases, celebrates yesterday's landmark executive order that would remove cannabis from a group of drugs classified as more dangerous than others, the so-called Schedule I drugs under the Controlled Substances Act. Cannabis' classification would become a Sch